

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **RESINCO CAPITAL PARTNERS INC. (“Resinco” or the “Issuer”)**.

Trading Symbol: **RIN**

Number of Outstanding Listed Securities: **122,186,007 Common shares were issued and outstanding as of March 31, 2019**

Date: **April 2, 2019 (for the month of March 2019)**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer is a global investment company which specializes in providing early stage financing to private and public companies as well as medical marijuana pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant position in early stage investment opportunities that adequately reflect the risk profile.**

**See Item 2 below for a summary of the Issuer's business and operations during the month of March 2019.**

2. Provide a general overview and discussion of the activities of management.

**During the month of March 2019, the Issuer's business and operations included:**

- **the entry into a letter agreement, through its wholly owned subsidiary ReFormation Pharmaceuticals Corp, with 180 Therapeutics LP ("180 Therapeutics"), pursuant to which 180 Therapeutics will provide a right of first negotiation with respect to the assets of its University of Oxford project focusing on promoting tissue repair and regeneration by targeting the body's own stem cells and enhancing their effectiveness; and**
- **general management and administrative matters.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**There were no new products or services developed or offered during the month of March 2019.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**There were no products or services discontinued during the month of March 2019.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services,

joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**The Issuer, through its wholly owned subsidiary ReFormation Pharmaceuticals Corp. (“ReFormation”), entered into a letter agreement with 180 Therapeutics LP (“180 Therapeutics”) (the “Agreement”) pursuant to which 180 Therapeutics will provide ReFormation the right of first negotiation in the event 180 Therapeutics completes its currently contemplated exclusive intellectual property agreement with the University of Oxford (the “Program”). Under the terms of the Agreement, 180 Therapeutics will negotiate exclusively with ReFormation (the “ROFN”) regarding a strategic transaction that would result in the acquisition of the Program or provide for an exclusive licensing, partnering or collaboration transaction between ReFormation and 180 Therapeutics. In consideration for the ROFN, ReFormation will pay US\$900,000 with a further US\$300,000 in tranches over the following 12 months. ReFormation has the option to extend the ROFN with 180 Therapeutics for an additional cash consideration of US\$1,800,000 payable in two equal tranches.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**There were no contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced, expired or were terminated during the month of March 2019.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**There were no asset acquisitions or dispositions by the Issuer during the month of March 2019.**

8. Describe the acquisition of new customers or loss of customers.

**There were no acquisitions of new customers or loss of customers during the month of March 2019.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of March 2019.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**There were no employee hirings, terminations or lay-offs during the month of March 2019.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**There were no labour disputes during the month of March 2019.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**There were no legal proceedings to which the Issuer became a party to during the month of March 2019.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**There was no indebtedness incurred or repaid by the Issuer during the month of March 2019.**

14. Provide details of any securities issued and options or warrants granted.

**During the month of March 2019, the following securities were issued:**

Date of Issue	Security	Number Issued	Details of Issuance
N/A			

15. Provide details of any loans to or by Related Persons.

**There were no loans to or by Related Persons during the month of March 2019.**

16. Provide details of any changes in directors, officers or committee members.

**During the month of March 2019, there were no changes in directors, officers or committee members.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion & Analysis dated November 29, 2018 (the "MD&A") under the heading "Risk Factors". The MD&A is available on the Issuer's SEDAR profile at [www.sedar.com](http://www.sedar.com).**

*[the balance of this page is left intentionally blank]*

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **April 2, 2019.**

**Alexander Somjen**  
 Name of Director or Senior  
 Officer

**"Alexander Somjen"**  
 Signature

**President & CEO**  
 Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer	For Month End	Date of Report YY/MM/D
<b>Resinco Capital Partners Inc.</b>	<b>March 2019</b>	<b>2019/04/02</b>
Issuer Address		
<b>789 West Pender Street, Suite 810</b>		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
<b>Vancouver, B.C., V6C 1H2</b>	<b>(604) 687-3141</b>	<b>(604) 687-2038</b>
Contact Name	Contact Position	Contact Telephone No.
<b>Theo van der Linde</b>	<b>CFO</b>	<b>(778) 834-6272</b>
Contact Email Address	Web Site Address	
<b>theo@pashleth.com</b>	<b>N/A</b>	